Pathological gambling caused by drugs used to treat Parkinson disease

Arch Neurol. 2005 Sep;62(9):1377-81. doi: 10.1001/archneur.62.9.noc50009. Epub 2005 Jul 11.


Background: Pathological gambling is a rare potential complication related to treatment of Parkinson disease (PD). However, the etiology of this behavior is poorly understood.

Objective: To examine the relationship between medical therapy for PD and pathological gambling.

Methods: In our routine movement disorders practice (2002-2004), we encountered 11 patients with idiopathic PD who had recently developed pathological gambling. We assessed the relationship to their medical therapy and compared them with cases identified by systematic review of the existing literature on pathological gambling and PD.

Results: All 11 patients with PD and pathological gambling were taking therapeutic doses of a dopamine agonist; 3 of these patients were not treated with levodopa. In 7 patients, pathological gambling developed within 3 months of starting to take or escalating the dose of the agonist; in the other 4 with a longer latency, gambling resolved after the agonist use was discontinued. Pramipexole dihydrochloride was the agonist in 9 of 11 cases in our series and 10 of 17 in the literature (68% in total).

Conclusions: Dopamine agonist therapy was associated with potentially reversible pathological gambling, and pramipexole was the medication predominantly implicated. This may relate to disproportionate stimulation of dopamine D(3) receptors, which are primarily localized to the limbic system.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / adverse effects*
  • Disruptive, Impulse Control, and Conduct Disorders / chemically induced*
  • Female
  • Gambling / psychology*
  • Humans
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Review Literature as Topic


  • Antiparkinson Agents
  • Levodopa